CenTrial Logo

The Potential of Sleep-Opt-In for Type 1 Diabetes Management

by


Clinical trial determines that digital intervention tools help diabetics sleep better

People with type 1 diabetes often experience sleep problems, which can further complicate their management of the condition. Some of the most common sleep problems in people with type 1 diabetes include insomnia, sleep apnea, restless leg syndrome, and delayed sleep phase syndrome.

Clinical Trial

A clinical trial tested whether a new technology-assisted sleep intervention called Sleep-Opt-In could help people with type 1 diabetes improve their sleep habits and overall health. Short sleep duration and irregular sleep schedules are known to cause problems with managing blood sugar levels in people with diabetes, so finding a way to improve sleep could be very beneficial.

The study involved 14 adults with type 1 diabetes randomly assigned to the Sleep-Opt-In or healthy living attention control groups. The control group received general health advice. The Sleep-Opt-In group received an 8-week intervention that included digital lessons, a sleep tracker, and weekly phone calls with a trained sleep coach.

To measure the effectiveness of the intervention, the researchers looked at various factors, including sleep (measured using a device called an actigraphy), glucose levels (measured using a continuous glucose monitoring system), and patient-reported outcomes (such as fatigue and mood). These measurements were taken at the beginning of the study and again after the 8-week intervention.

Results

Sleep-Opt-In was feasible and acceptable to participants. Those in the Sleep-Opt-In group who had short or irregular sleep patterns saw improvements in their sleep regularity, with an average increase of 25 minutes of sleep per night. They also had lower glycemic variability (a measure of blood sugar fluctuations) and spent more time within a healthy range of blood sugar levels (an increase of 6.9%). The Sleep-Opt-In group also reported improvements in fatigue and depressive mood compared to the control group.

These findings suggest that Sleep-Opt-In could be a promising intervention for improving sleep habits and overall health in people with type 1 diabetes. The remote delivery of the intervention using digital technology and coaching could make it more accessible to a broader population. However, further research is needed to confirm these results and to determine the long-term effects of Sleep-Opt-In on health outcomes.

Conclusion

This study proves that a technology-assisted sleep intervention called Sleep-Opt-In is feasible, acceptable, and effective in improving sleep habits and health outcomes in people with type 1 diabetes. The findings suggest that Sleep-Opt-In could be a valuable tool for healthcare providers to improve the management of diabetes in their patients.
__________



Share this article with a friend:
     


Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Whether you're healthy or have a medical condition you can participate in a clinical trial.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.


This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.